Injection of Active Allogeneic Natural Killer Cells in Patients With Gliomas

Launched by MARZIEH EBRAHIMI · Nov 12, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment for patients with gliomas, which are a type of brain tumor. Specifically, the trial is looking at the use of natural killer (NK) cells, a type of immune cell that can help the body fight cancer. Gliomas can be aggressive and are often difficult to treat with standard methods like surgery and radiation. Researchers hope that using NK cells will improve outcomes for patients with high-grade gliomas, which are particularly challenging.

To participate in this trial, patients need to be newly diagnosed with certain types of high-grade gliomas (grades 3 or 4) and be between 3 and 60 years old. They should also be in good overall health, meaning they can carry out daily activities without much trouble. Participants will receive the NK cell treatment and will be closely monitored throughout the trial. It’s important to know that this study is in the recruiting phase, so eligible patients can still join. If you or someone you know is facing a glioma diagnosis, this trial could be a potential option to explore.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria: New diagnosed patients with grade 3 or 4 brain tumor, based on WHO classification, which are included in the one of the following conditions: • Astrocytoma, IDHmutant • Oligodendroglioma, IDH-mutant • Glioblastoma, IDH-wild type • Diffuse midline glioma • Diffuse hemispheric glioma • Diffuse pediatric-type high-grade glioma, IDH-wild type Age range of 3 to 60 years old both sex Lansky/Karnofsky performance score above 60 Obtained informed consent of patients or parents or legal attendance in cases of pediatrics Hemoglobin above 10 gr/dL of blood Absolute granulocyte count (AGC) above 500 per microliter of blood Platelet count above 50000 per microliter of blood INR below 2 and PTT less than 1.5 times of maximum normal value Plasma bilirubin level less than 1.5 times of maximum normal value Plasma hepatic transaminases (ALT and AST) level less than 3 times of maximum normal value Plasma creatinine level less than 1.5 times of maximum normal value -
• • Exclusion Criteria: Evidence of radio necrosis in MRI or MRS Intolerance of new treatment due to emergency condition History of other malignancies History of any immunodeficiency diseases or any immune compromising conditions Rupture of cerebral shunt or unable to perform a lumbar puncture Pregnancy History of uncontrolled chronic diseases such as: Diabetes, CHF, liver cirrhosis, CKD, etc
• • -